反应详情

A solution of 6-methoxy-4-(2-methylindol-5-yloxy)-7-(1-tert-butoxycarbonylpiperidin-4-ylmethoxy)quinazoline (155 mg, 0.3 mmol), (prepared as described in Example 69), in methylene chloride (5 ml) containing TFA (1 ml) was stirred at ambient temperature for 30 minutes. The volatiles were removed under vacuum and the residue was treated with water and adjusted to pH12 with 2M sodium hydroxide. The mixture was extracted with methylene chloride. The organic layer was dried (MgSO4), and the volatiles were removed by evaporation. The residue was purified by column chromatography eluting with methylene chloride/ethyl acetate/methanol (5/4/1) followed by methylene chloride/methanol (9/1) and by 3M ammonia in methanol/methanol/methylene chloride (5/15/80). After removal of the solvent by evaporation, the residue was dissolved in the minimum of methylene chloride, ether was added followed by petroleum ether. The precipitate was collected by filtration, washed with ether and dried under vacuum to give 6-methoxy-4-(2-methylindol-5-yloxy)-7-(piperidin-4-ylmethoxy)quinazoline (120 mg, 96%).

1. customThe volatiles were removed under vacuum
2. additionthe residue was treated with water
3. extractionThe mixture was extracted with methylene chloride
4. dry with materialThe organic layer was dried (MgSO4)
5. customthe volatiles were removed by evaporation
6. customThe residue was purified by column chromatography
7. washeluting with methylene chloride/ethyl acetate/methanol (5/4/1)
8. customAfter removal of the solvent
9. customby evaporation
10. dissolutionthe residue was dissolved in the minimum of methylene chloride, ether
11. additionwas added
12. filtrationThe precipitate was collected by filtration
13. washwashed with ether
14. customdried under vacuum